Paxlovid: antiviral drug against Covid-19 is 89% effective according to Pfizer – Money

Paxlovid | Paxlovid: the antiviral drug against Covid – 16 is effective at 89% according to Pfizer. Getty Images

Pharmaceutical company Pfizer said the final clinical trial analysis of its Covid antiviral treatment – 19, Paxlovid, has confirmed that it is effective at 89% to prevent hospitalizations and death in high-risk patients if his tablet is taken within three days of symptom onset.

“This news confirms that the oral antiviral, if authorized or approved, could have a significant impact on the lives of many people,” said Albert Bourla , CEO of Pfizer, in a press release.

Paxlovid is a type of antiviral drug called a protease inhibitor. This class of drugs has been successfully deployed against diseases such as HIV and hepatitis C. The drug works by preventing SARS-CoV-2, the virus responsible for Covid – 19, to produce the proteins it needs to replicate. This helps reduce the amount of virus in the patient, which helps prevent serious illness.

Pfizer also claims that the results of its study, which have yet to be been peer reviewed, prevented hospitalizations and deaths in 70% of cases in patients who have taken the medicine within 5 days of symptom onset. This study, which involved 2 89 patients, was a randomized controlled study in which some patients received the antiviral drug while others received a placebo.

The company also published an interim review of a still-ongoing study of the drug in patients who had either standard (rather than high) risk of Covid – 16, or were vaccinated but had a or more risk factors for serious illness. Interim analysis revealed that the drug was 30% effective in preventing hospitalizations in this population, but did not meet one of the primary study objectives, which was to see if the drug could relieve symptoms of the disease for four consecutive days.

In addition to the analysis of clinical trials, Pfizer also said that laboratory studies of its antiviral drug determined that it should still work to prevent viral replication in the Omicron variant of the coronavirus, which means it should still work against people infected with this virus.

Pfizer submitted an emergency clearance request for Paxlovid to the FDA on 16 November. An FDA panel narrowly recommended the authorization of another antiviral, co-developed by Merck and Ridgeback therapeutics, the 19 November, but this drug has not yet been approved by the agency. The two companies signed an agreement with the United Nations Medicines Patent Pool to allow generic drug makers in low-income countries to manufacture the drug without paying license fees as long as the Covid pandemic – 19 is in progress.

This news Data on the efficacy of Paxlovid, CEO Albert Bourla said in a statement, “underscore the potential of the candidate treatment to save the lives of patients worldwide, whether or not they have been vaccinated.”

Article translated from Forbes US – Author: Alex Knapp

Also read: Covid – 16: UK approves treatment by antibody developed by GSK